基于态靶理论探讨糖尿病肾病的核心病态与治疗
Research on the core pathological states and target-based drug application in the diagnosis and treatment of diabetic kidney disease based on the state-target theory
糖尿病肾病(DKD)为糖尿病的核心微血管并发症,早期症状隐匿、病理机制复杂,临床面临“态强靶弱”与“刻强轴弱”双重困境。本研究基于仝小林“态靶辨治”理论,结合DKD病理生理特征,凝练出以“虚、瘀、浊”三态为核心的病态特征,通过分期调态方干预核心病态,并针对水肿、呕吐等症靶选取症靶药;定向调控肌酐、尿蛋白等标靶指标。融合中医学理论与现代药理机制,为DKD精准防治提供“整体调态”与“定向打靶”的策略体系。
Diabetic kidney disease (DKD), as a core microvascular complication of diabetes, presents with insidious early symptoms and complex pathological mechanisms. Clinically, it faces the dual dilemmas of "overemphasis on states while overlooking targets" (tai qiang ba ruo) and "strong in short-term interventions but weak in a systemic regulation" (ke qiang zhou ruo). Based on Academician Tong Xiaolin's state-target differentiation and treatment theory (tai ba bian zhi), and integrating the pathophysiological characteristics of DKD, this study crystallizes "deficiency, stasis, and turbidity" (xu, yu, zhuo) as its core pathological states, and proposes to manage them with stage-specific formulas. As for its symptom targets such as edema, vomiting, etc., it is advised that targeted medications are precisely selected. In addition, targeted regulations are argued to be directed at those critical biomarkers (e. g., creatinine, urine protein). By synergizing the traditional Chinese medicine theory with modern pharmacological mechanisms, this framework provides an integrated strategy for a precise DKD management, combining holistic state regulation (zheng ti tiao tai) with directional target intervention (ding xiang da ba).
| [1] |
|
| [2] |
中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J]. 中华糖尿病杂志, 2025, 17(1):16-139. |
| [3] |
李文歌,李平,王明, |
| [4] |
张莉莉,王蕾,周毅徳, |
| [5] |
郝瑞,李敏,苟筱雯, |
| [6] |
余江毅,倪青,刘苏.糖尿病肾病病证结合诊疗指南[J]. 中医杂志, 2022, 63(2):190-197. |
| [7] |
莫超,赵洁,黄国东.基于文献的糖尿病肾脏病患者中医证候及证素分布规律研究[J]. 中医杂志, 2023, 64(8):848-852. |
| [8] |
吕琦,卢姚宏,查青林, |
| [9] |
李雪,高菁,郑时静, |
| [10] |
吴以岭,魏聪,贾振华, |
| [11] |
陈亮,丁英钧.赵玉庸治疗糖尿病肾病经验[J]. 中华中医药杂志, 2020, 35(1):244-247. |
| [12] |
韩飞,王耀献,刘兰英, |
| [13] |
周富明.溺毒辨治十法[J]. 浙江中医杂志, 2019, 54(7):471-474. |
| [14] |
肖遥,赵进喜.赵进喜治疗糖尿病肾病经验[J]. 中华中医药杂志, 2018, 33(1):159-162. |
| [15] |
吴平,邱晓堂,李赫男, |
| [16] |
杨娟娟,吕忠美,王姝琴.六味地黄丸联合辛伐他汀对肾阴亏损型糖尿病肾病病人炎症免疫指标和肾纤维化的影响[J]. 中西医结合心脑血管病杂志, 2022, 20(12):2241-2244. |
| [17] |
吴源陶,王智槟,傅馨莹, |
| [18] |
刘爱娇.真武汤合附子理中丸加减方治疗糖尿病肾病60例临床观察[J]. 湖南中医杂志, 2022, 38(8):17-21. |
| [19] |
侯文雁,宋玮,吴敬, |
| [20] |
中国中西医结合学会内分泌专业委员会糖尿病肾脏病专家委员会,中国微循环学会中医与微循环专业委员会.糖尿病肾脏病中西医结合防治专家共识(2023版)[J]. 中华糖尿病杂志, 2023, 15(8):690-702. |
| [21] |
苗常鑫.加味桂枝茯苓丸治疗早期糖尿病肾脏病的临床疗效及机制研究[D]. 沈阳: 辽宁中医药大学, 2024. |
| [22] |
左田,周卓宁.基于网络药理学探讨桂枝茯苓丸治疗糖尿病肾病的作用机制[J]. 中医临床研究, 2023, 15(6):40-47. |
| [23] |
刘文科,周强,甄仲, |
| [24] |
贺璞玉,倪青.倪青治疗糖尿病肾病的思路与方法[J]. 中医药导报, 2022, 28(2):184-187, 192. |
| [25] |
马德睿,张莹,黄琛, |
| [26] |
郑云鹏,马超.老年早期糖尿病肾病水肿应用复方五苓散治疗的临床疗效[J]. 内蒙古中医药, 2023, 42(8):88-89. |
| [27] |
阙嘉露,庞彩霞,李方园, |
| [28] |
文浩维,徐健婷,曾纪斌.真武汤加味治疗糖尿病肾病综合征患者的临床疗效及对其肾损伤、氧化应激及炎症因子的影响[J]. 世界中西医结合杂志, 2024, 19(10):2032-2037. |
| [29] |
李怡诺,李力恒,张宇飞, |
| [30] |
张李博,孙路,吴金鸿, |
| [31] |
陈斯琪,聂克.基于网络药理学探讨小半夏汤防治化疗性恶心呕吐的作用机制[J].中国实验方剂学杂志, 2020, 26(3):156-165. |
| [32] |
郑秋惠,杨明珠,龚自坤, |
| [33] |
施莹,赖龙胜,黄腾蛟, |
| [34] |
中华医学会肾脏病学分会专家组.糖尿病肾脏疾病诊断、预后评估和生物标志物应用专家共识[J]. 中华肾脏病杂志, 2022, 38(8):771-784. |
| [35] |
陈银凤,闵捷,俞东容.从脾肾亏虚为本论治慢性肾衰探析[J]. 浙江中医杂志, 2023, 58(11):807-808. |
| [36] |
何望,黄国顺,张凯钰, |
| [37] |
张婷,丁汉荣.丹参注射液治疗糖尿病肾病的效果及对患者血压的影响[J]. 临床医学研究与实践, 2019, 4(26):48-49. |
| [38] |
张永学,张素媛,徐佳佳.丹参酮ⅡA磺酸钠调控Nox4/TGF-β1/p-Smad通路对高糖诱导人肾小球系膜细胞损伤的保护作用[J]. 山西中医药大学学报, 2024, 25(11):1209-1216. |
| [39] |
管陈安,陈德君,段学峰, |
| [40] |
马佳颖,杨小慧,彭苗, |
| [41] |
王蕊花,孙大林,王金晶, |
| [42] |
宫璞,王晴,赵振.益母草碱对原发性肾病综合征大鼠的影响[J]. 中国临床药理学杂志, 2024, 40(11):1603-1607. |
| [43] |
王晶,闫晓辉,王晓明, |
| [44] |
孙杰瑜,孙博蕊.土茯苓总黄酮通过p38/ERK MAPK通路调控膜性肾病大鼠足细胞上皮-间充质转化的作用机制研究[J]. 中医药导报, 2022, 28(4):1-5, 22. |
/
| 〈 |
|
〉 |